Novo Nordisk's pricing tactics from the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who has accused the company of cost gouging, pointing out the stark contrast involving U.S. selling prices and those in Europe and copyright.In October 2024, Novo Nordisk posted a study on scientific journal Nature a few novel glucose-sensit… Read More